Prognosis and ablation success in thyroid cancer: overcoming the challenges of incomplete clinical profiles

甲状腺癌 医学 烧蚀 癌症 甲状腺 放射科 内科学
作者
Manish Ora,Aftab Hasan Nazar,Prabhakar Mishra,Sukanta Barai,Amitabh Arya,Prasanta Kumar Pradhan,Sanjay Gambhir
出处
期刊:Nuclear Medicine Communications [Lippincott Williams & Wilkins]
卷期号:46 (1): 21-27
标识
DOI:10.1097/mnm.0000000000001923
摘要

BACKGROUND: Differentiated thyroid carcinoma (DTC) is managed by surgery followed by radioiodine (RAI) therapy in most intermediate and high-risk patients. Most nonmetastatic patients have excellent treatment responses and have long-term disease-free status. A lack of comprehensive medical services in resource-limited nation leads to attrition of critical clinical prognostication information. This study aimed to identify readily available clinical, biochemical, and histopathological parameters to predict remnant ablation success and long-term outcomes. METHODS: The study included DTC patients who underwent RAI after surgery. Ablation success was determined by thyroglobulin (Tg) and whole-body radioiodine scan. Patients were followed for at least 5 years to assess biochemical incomplete response (BIR) and structural recurrence. RESULTS: The study included 383 patients (a mean age of 37.8 ± 12.9 years). Successful ablation was noted in 251 (65.5%). High preablative stimulated serum Tg (presTg), papillary variants, and central and lateral compartment lymph nodal metastases were associated with ablation failure. PresTg ( P < 0.001) was the most significant predictor. After a 102.9 ± 34.5 months follow-up, 280 (73.1%) patients were disease-free. BIR and structural recurrence were noted in 103 and 32 patients. PresTg (8.1 ± 27.7 vs. 92.3 ± 99.9 ng/ml), ATg (112.9 ± 389.8 vs. 43.2 ± 89.8 IU/ml), papillary variant, central [109 (66.1%) vs. 56 (33.9%)], and lateral compartment [65 (63.7%) vs. 37 (36.3%) lymph nodal metastases were associated ( P < 0.05) with BIR. PresTg >10.5 ng/ml has a sensitivity and specificity of 86.6 and 86.0% for predicting BIR. Patients with successful remnant ablation and a presTg level <10.5 ng/ml had a low risk of long-term disease recurrence (less than 5%). CONCLUSION: This ambispective study found that successful ablation and long-term disease-free survival were achievable in a significant proportion of DTC patients. BIR (26.9%) and structural recurrence (8.4%) were not uncommon. PresTg levels emerged as a crucial predictor of ablation success and subsequent outcomes. In resource-limited regions, presTg levels and ablation failure can aid in optimizing treatment strategies and improving patient care.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无花果的应助被steplight采纳,获得10
1秒前
领导范儿的应助被steplight采纳,获得10
1秒前
万能图书馆的应助被steplight采纳,获得10
1秒前
今后的应助被steplight采纳,获得10
2秒前
温暖的以筠完成签到,获得积分20
2秒前
2秒前
已巳己完成签到,获得积分10
3秒前
chen555完成签到,获得积分10
4秒前
K. G.完成签到,获得积分10
4秒前
4秒前
5秒前
5秒前
7秒前
Redinn完成签到,获得积分10
7秒前
7秒前
万重山完成签到 ,获得积分10
7秒前
顾矜的应助被薛定谔的猫采纳,获得10
7秒前
lius完成签到,获得积分10
9秒前
Akim的应助被steplight采纳,获得10
9秒前
情怀的应助被steplight采纳,获得10
9秒前
李健的应助被steplight采纳,获得10
9秒前
rongliy发布了新的文献求助10
9秒前
打打的应助被steplight采纳,获得10
9秒前
斯文败类的应助被steplight采纳,获得10
10秒前
爆米花的应助被steplight采纳,获得10
10秒前
大个的应助被steplight采纳,获得10
10秒前
10秒前
Ava的应助被steplight采纳,获得10
10秒前
科目三的应助被steplight采纳,获得10
10秒前
在水一方的应助被steplight采纳,获得10
10秒前
糊糊完成签到,获得积分10
10秒前
11秒前
11秒前
11秒前
flying发布了新的文献求助60
13秒前
sleep完成签到,获得积分10
13秒前
14秒前
洋洋芋发布了新的文献求助10
15秒前
可一可再完成签到 ,获得积分10
16秒前
方方土完成签到,获得积分20
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188353
求助须知:如何正确求助?哪些是违规求助? 9576169
关于积分的说明 21845860
捐赠科研通 7786410
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482235